Latest Regulatory Engagement News

MyEco Group Ltd has reported record quarterly sales of its MyEcoBag® products, alongside improved gross margins and a significant reduction in operating cash outflows following a strategic operational restructure.

Torque Metals is advancing its Paris Gold Camp project in Western Australia, moving from exploration to development readiness with a 250,000-ounce gold resource and an aggressive drilling program.

Finder Energy Holdings has completed the acquisition of the Petrojarl I FPSO, a critical step that de-risks the KTJ Project and accelerates its path to a Final Investment Decision expected by mid-2026. The company also secured A$25 million in funding and achieved a significant resource upgrade.

Echo IQ has completed clinical validation of its EchoSolv HF heart failure detection software with the Mayo Clinic Platform, achieving outstanding accuracy. The company has now formally submitted its FDA 510(k) clearance application, positioning itself for significant commercial expansion in the US healthcare market.

NH3 Clean Energy has marked significant progress in its WAH2 clean ammonia project, securing major offtake agreements and government facilitation support alongside a $4 million institutional funding round.

Entropy Neurodynamics reports encouraging early clinical results from the first patient treated with TRP-8803, an IV-infused psilocin therapy for Binge Eating Disorder, showing improvements across multiple symptom areas.

Insignia Financial’s Funds Under Management and Administration edged up to $342 billion, driven by strong inflows into its Wrap platform and multi-asset solutions, while Master Trust funds faced ongoing outflows amid product transitions.

NobleOak Life Limited has increased its stamp duty provision to $6.5 million following a dispute with the Victorian State Revenue Office over exemption eligibility, prompting pricing changes and ongoing regulatory engagement.

NeuroScientific Biopharmaceuticals reports encouraging clinical responses in fistulising Crohn’s disease patients treated under Australia’s Special Access Scheme, setting the stage for pivotal Phase 2 trials later this year.

AdAlta Limited has raised A$1.2 million through a strategic placement to advance its innovative PD1 armored MSLN CAR-T therapy for solid cancers, reinforcing its unique 'East to West' cellular immunotherapy approach.

Island Pharmaceuticals reports ongoing FDA review of its antiviral Galidesivir, with no adverse feedback received as the regulator takes extra time to finalise guidance.

Neurizon Therapeutics has progressed its ALS treatment NUZ-001 into critical clinical trial phases, even as the FDA declines its Fast Track Designation request pending more data.